Lophius Biosciences Presents Scientific Results with T-Track® CMV and T-Track® EBV Tests and Receives Award
Besides a detailed presentation of the recent clinical validation study, the company also presented first results concerning the application of both CE-marked tests as standardized assay systems for the determination of the cell-mediated immune response in transplant patients. In appreciation for the scientific quality of the presented work, Lophius Biosciences received the poster award at the meeting of the German Society for Nephrology (DGfN) in Hamburg.
"We are very pleased about the feedback and recognition we have gained for our scientific work for both T-Track® CMV and T-Track® EBV tests. This will provide a strong support for our aim to establish full clinical benefits of these novel T-cell based diagnostics in the field of transplantation and other indications with high medical need" said Dr. Michael Lutz, CEO of Lophius Biosciences.
Lophius Biosciences GmbH
Lophius Biosciences GmbH develops and markets innovative T-cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
Alibaba und Mediatek verkünden IoT-Kooperation
Der Chip-Entwickler Mediatek und Chinas IT-Gigant Alibaba bündeln ihr Know-How. Mit der Zusammenarbeit wollen beide Unternehmen den Aufbau eines sprachgesteuerten Ökosystems für intelligente Haustechnik forcieren.Weiterlesen